BioSpace News Archive

iQure Pharma Inc. (iQure), a CNS company dedicated to the development of new epilepsy and pain management therapeutics, has completed the first closing of its latest round of funding.

ImmunoPrecise Antibodies Ltd., an AI-driven biotherapeutic research and technology company wishes to provide an update on its overall growth strategy, particularly in light of recent market developments.

Alzamend Neuro, Inc. today announced that it has submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with MDD.

Adlai Nortye Ltd. and Nucleai is pleased to announce the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.

Abiomed, part of Johnson & Johnson MedTech1, announced that novel data from seven research studies focused on optimizing outcomes for patients receiving Impella-supported high-risk percutaneous coronary intervention (HRPCI) will be presented at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium taking place in San Francisco between Oct. 24 - 26.

Mission Bio announced today initial results from the National Institute of Standards and Technology (NIST) Genome Editing Consortium’s inaugural Interlab Study.

Cyclo Therapeutics, Inc. today announced that it had entered into a securities purchase agreement with certain accredited investors (the “Investors”) to raise $2,359,584 in a private offering (the “Offering”).

Apollomics Inc., announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress 2023, being held in Madrid, Spain from October 20-24, 2023.

Elevar Therapeutics, Inc. today announced the hiring of Brian Cunningham as vice president of sales and Kenneth Rankin as vice president of market access.

Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2-expressing advanced solid tumors.